After a 2022 failure, Merck’s mega-blockbuster has rallied in head and neck cancer. The company dropped data from a successful Phase III trial as a perioperative treatment for patients with late stage, resected, locally advanced head and neck squamous cell carcinoma. In the KEYNOTE-689 trial, Keytruda was used as a neoadjuvant then continued after surgery […]
The post Keytruda Redeems Itself in Head and Neck Cancer as Merck Lands Potential $1.9B I&I Collab first appeared on San Francisco News.
—-
Author : SanFrancisco
Publish date : 2024-10-08 14:45:11
Copyright for syndicated content belongs to the linked Source.